NCT00946712
Clinical Trial Information
Trial Number: NCT00946712 (ClinicalTrials.gov)
Disease Type:
- Lung, Mediastinal and Pleural Neoplasm - Non-Small Cell Lung Cancer
Trial Title:
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Study ID:
S0819
Images are available?:
Yes
Imaging data can be requested via the NCTN/NCORP Data Archive. To view imaging data details before requesting data here, visit:
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00946712-D3 | There are three data submissions associated with PMID 29169877: NCT00946712-D1, -D2, and -D3. This dataset, NCT00946712-D3, will allow users to reproduce the results reported in the Lancet Oncology (Herbst et al., Lancet Oncology, 2018). This dataset contains reasons for off treatment due to toxicity. |
| NCT00946712-D2 | There are three data submissions associated with PMID 29169877: NCT00946712-D1, -D2, and -D3. This toxicity dataset, NCT00946712-D2, will allow users to reproduce the results reported in the Lancet Oncology (Herbst et al., Lancet Oncology, 2018). This dataset contains event-level information (one row per patient per adverse event experienced on trial). |
| NCT00946712-D1 | There are three data submissions associated with PMID 29169877: NCT00946712-D1 , -D2, and -D3. This clinical dataset, NCT00946712-D1, will allow users to reproduce the results reported in the Lancet Oncology (Herbst et al., Lancet Oncology, 2018). This dataset contains patient-level data (one row per patient), including eligibility, evaluability, treatment, demographic, and baseline information. It also contains assessment data. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®